Looking at the universe of stocks we cover at Dividend Channel, on 6/2/16, PDL BioPharma Inc (PDLI - Get Report) will trade ex-dividend, for its quarterly dividend of $0.05, payable on 6/13/16. As a percentage of PDLI's recent stock price of $3.36, this dividend works out to approximately 1.49%, so look for shares of PDL BioPharma Inc to trade 1.49% lower — all else being equal — when PDLI shares open for trading on 6/2/16.Below is a dividend history chart for PDLI, showing historical dividends prior to the most recent $0.05 declared by PDL BioPharma Inc: In general, dividends are not always predictable; but looking at the history above can help in judging whether the most recent dividend from PDLI is likely to continue, and whether the current estimated yield of 5.95% on annualized basis is a reasonable expectation of annual yield going forward. The chart below shows the one year performance of PDLI shares, versus its 200 day moving average: Looking at the chart above, PDLI's low point in its 52 week range is $2.58 per share, with $6.78 as the 52 week high point — that compares with a last trade of $3.36. In Tuesday trading, PDL BioPharma Inc shares are currently up about 0.6% on the day.
More from Stocks
Boeing Slumps After Report Says Planemaker May Have Misled FAA on 737 MAX
Boeing shares fell the most in more than seven months Friday after a report said the Federal Aviation Administration demanded the planemaker turn over internal communications that questioned the safety of software linked to the grounded 737 MAX jet.
Tesla Reports Earnings on Wednesday: 3 Key Things to Watch For
The keys to Tesla's earnings report are all drivers of the company's ability to become consistently profitable.
Brexit: UK Prime Minister Boris Johnson Loses Key Vote to Avoid EU Exit Delay
U.K. lawmakers voted Saturday to delay approval of Prime Minister Boris Johnson's Brexit deal, setting up a potentially unprecedented clash between the country's ruling party and the Supreme Court.
Zuckerberg Set to Defend Libra on Capitol Hill Next Week. Here's What to Expect
While the hearing is focused on Facebook's Libra project, the congressional grilling could also extend to Facebook's acquisitions, antitrust concerns and posture on free speech.